About Vivostat
Vivostat is a company based in Allerød (Denmark) founded in 2001 was acquired by Principal Technologies in February 2024. Vivostat has raised $12.89 million across 6 funding rounds from investors including European Union, Principal Technologies and EIC Fund. Vivostat offers products and services including Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin. Vivostat operates in a competitive market with competitors including PrognomiQ, PreOmics, LenioBio, Expedeon and List Biological Laboratories, among others.
- Headquarter Allerød, Denmark
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vivostat A/S
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.89 M (USD)
in 6 rounds
-
Latest Funding Round
$55.08 K (USD), Grant
Apr 30, 2023
-
Investors
European Union
& 2 more
-
Employee Count
Not available
-
Acquired by
Principal Technologies
(Feb 06, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vivostat
Vivostat offers a comprehensive portfolio of products and services, including Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin.
System for on-site preparation of autologous fibrin for surgery
Matrix for arthroscopic surgery to support tissue regeneration
Matrix for gastrointestinal surgery to aid healing
Matrix for fistula treatment in minimally invasive procedures
Sealant for surgical applications to promote hemostasis
Funding Insights of Vivostat
Vivostat has successfully raised a total of $12.89M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $55.08 thousand completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vivostat
Vivostat has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Principal Technologies and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Healthcare investments are targeted by Principal Technologies private equity fund.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Vivostat
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vivostat
Investment portfolio details for Vivostat
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vivostat
Detailed financials for Vivostat
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vivostat Comparisons
Peer comparison for Vivostat
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vivostat
Vivostat operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PrognomiQ, PreOmics, LenioBio, Expedeon and List Biological Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of tests for the detection and treatment of cancer and other diseases
|
|
| Locked | Locked | Locked |
Reagents and instruments for proteomics research are supplied by PreOmics.
|
|
| Locked | Locked | Locked |
Kits for cell-free eukaryotic protein expression are provided.
|
|
| Locked | Locked | Locked |
Reagents and kits for protein-based research are developed and supplied.
|
|
| Locked | Locked | Locked |
Specializes in the production of research reagents
|
Detailed competitors of Vivostat
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vivostat
Complete news archive for Vivostat
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivostat
Vivostat was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Vivostat is headquartered in Allerød, Denmark.
Vivostat is a funded company, having raised a total of $12.89M across 6 funding rounds to date.
Vivostat was founded in 2001 in Alleroed, Denmark, and operates in the medical device sector focused on autologous blood processing. Systems for on-site preparation of fibrin sealants are developed, with the Vivostat system enabling reproducible platelet-rich plasma production without cryoprecipitation or external thrombin. The setup includes a processor for blood handling, an applicator for site-specific delivery, and disposable collection components, supporting surgical applications across clinical settings.
Vivostat offers Vivostat System, ArthroZheal, Obsidian ASG, Obsidian RFT, and Vivostat Fibrin.
Vivostat has 3 investors. Key investors include European Union, Principal Technologies, and EIC Fund.